Evotec SE to Announce Q1 2025 Results on May 6

Evotec SE, a life science company listed on both the Frankfurt Stock Exchange and NASDAQ, is scheduled to release its interim statement for the first quarter of 2025 on May 6. The announcement will be supplemented by a conference call, during which company representatives will discuss the results and provide a performance update. The call, conducted in English, allows participants to follow along with presentation slides synchronized to the audio, accessible through a webcast or by dialing in after pre-registration.

Evotec operates globally and collaborates with leading pharmaceutical and biotechnology entities. The company is focused on discovering and developing therapeutics in several therapeutic areas, including neurology and oncology. Further information, including the on-demand webcast, will be available on Evotec’s website.